Vaccine Targets 50M Doses Annually in Saudi

A Saudi company specializing in vaccine production plans to begin manufacturing its first vaccine by the end of 2027, with a production line capable of producing between 30 and 50 million doses annually. The focus will be on the seasonal influenza vaccine, which is based on cell technology and has been registered and approved by the Saudi Food and Drug Authority. The company aims to localize 80% of Saudi Arabia's vaccine needs and to expand later into exporting up to 25% of its total business. More than 60% of the expertise involved in the project are Saudi nationals. Additionally, the company has signed an agreement with CSL Seqirus and the Ministry of Health to ensure production readiness for future pandemics, part of the vaccine industry localization strategy launched by the Crown Prince in January 2024.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل